- Home
- FUTU vs WAT Comparison
FUTU vs WAT Comparison
Compare FUTU & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FUTU | WAT |
|---|---|---|
| Founded | 2011 | 1958 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7B | 32.7B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FUTU | WAT |
|---|---|---|
| Price | $152.64 | $297.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 17 |
| Target Price | $208.60 | ★ $386.38 |
| AVG Volume (30 Days) | 1.3M | ★ 1.4M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.47 |
| EPS | N/A | ★ 10.76 |
| Revenue | N/A | ★ $3,165,286,000.00 |
| Revenue This Year | $86.68 | $104.66 |
| Revenue Next Year | $14.95 | $10.53 |
| P/E Ratio | ★ $17.05 | $27.66 |
| Revenue Growth | N/A | ★ 6.99 |
| 52 Week Low | $70.60 | $275.05 |
| 52 Week High | $202.53 | $414.15 |
Technical Indicators
Market Signals| Indicator | FUTU | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 50.72 | 29.01 |
| Support Level | $152.48 | $281.33 |
| Resistance Level | $156.05 | $308.14 |
| Average True Range (ATR) | 5.15 | 8.92 |
| MACD | 1.04 | -0.20 |
| Stochastic Oscillator | 82.20 | 6.94 |
Price Performance
Historical ComparisonAbout FUTU Futu Holdings Limited
Futu Holdings Ltd is an online broker providing one-stop online investing services. The company provides its services through its digital platform Futu NiuNiu, which includes market data, trading service, and news feed of Hong Kong, Mainland China, Singapore, and the United States equity markets. It generates its revenue in the form of brokerage commission and handling charge services, and interest income.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.